TNXP · Tonix Pharmaceuticals Holding Corp. Common Stock
View on chartInsiders & Stakes
| Seth Lederman Chief Executive Officer | ▲ Buy | Open Market | 11,005 Shares held | 8/27/2026 | View profile |
| Richard Newcomb Stillwell Director | ▲ Buy | Open Market | 5,000 Shares held | 6/8/2026 | View profile |
| Bradley Saenger Chief Financial Officer | ▼ Sell | Other | 2,154 Shares held | 6/30/2026 | View profile |
| Carolyn E. Taylor Director | ▲ Buy | Open Market | 1,833 Shares held | 6/12/2026 | View profile |
| Richard H. Bagger Director | ▲ Buy | Open Market | 1,000 Shares held | 8/20/2026 | View profile |
| James Treco Director | ▲ Buy | Open Market | 250 Shares held | 8/20/2025 | View profile |
| Adeoye Y. Olukotun Director | ▼ Sell | Other | 0 Shares held | 6/10/2024 | View profile |
| Margaret Smith Bell Director | ▼ Sell | Other | 0 Shares held | 2/5/2025 | View profile |
| Gregory M. Sullivan Chief Medical Officer | ▼ Sell | Other | 0 Shares held | 2/5/2025 | View profile |
| Jessica Edgar Morris Chief Operating Officer | ▼ Sell | Other | 0 Shares held | 2/5/2025 | View profile |
Transaction History
| Seth Lederman | ▲ Buy | Open Market | 2,000 | $28K | 8/27/2026 |
| Richard H. Bagger | ▲ Buy | Open Market | 1,000 | $13K | 8/20/2026 |
| Bradley Saenger | ▼ Sell | Other | 1,453 | $16K | 6/30/2026 |
| Carolyn E. Taylor | ▲ Buy | Open Market | 1,415 | $15K | 6/12/2026 |
| Seth Lederman | ▲ Buy | Open Market | 5,000 | $59K | 6/9/2026 |
| Richard Newcomb Stillwell | ▲ Buy | Open Market | 5,000 | $58K | 6/8/2026 |
| Seth Lederman | ▲ Buy | Open Market | 5,000 | $63K | 3/31/2026 |
| Seth Lederman | ▲ Buy | Open Market | 15,000 | $223K | 3/18/2026 |
| Carolyn E. Taylor | ▲ Buy | Open Market | 418 | $15K | 8/21/2025 |
| James Treco | ▲ Buy | Open Market | 250 | $9K | 8/20/2025 |
| Seth Lederman | ▲ Buy | Open Market | 4,000 | $86K | 5/15/2025 |
| Seth Lederman | ▼ Sell | Other | 5 | $18 | 2/5/2025 |
| Seth Lederman | ▼ Sell | Other | 0 | $1 | 2/5/2025 |
| Seth Lederman | ▼ Sell | Other | 1 | $0 | 2/5/2025 |
| Jessica Edgar Morris | ▼ Sell | Other | 1 | $0 | 2/5/2025 |
| Margaret Smith Bell | ▼ Sell | Other | 1 | $0 | 2/5/2025 |
| James Treco | ▼ Sell | Other | 0 | $0 | 2/5/2025 |
| Richard H. Bagger | ▼ Sell | Other | 0 | $0 | 2/5/2025 |
| Bradley Saenger | ▼ Sell | Other | 0 | $0 | 2/5/2025 |
| Gregory M. Sullivan | ▼ Sell | Other | 0 | $0 | 2/5/2025 |
| Adeoye Y. Olukotun | ▼ Sell | Other | 1 | $2 | 6/10/2024 |
| Seth Lederman | ▲ Buy | Open Market | 20,000 | $34K | 6/29/2022 |
| Seth Lederman | ▲ Buy | Open Market | 100,000 | $25K | 3/25/2022 |
| Seth Lederman | ▲ Buy | Open Market | 12,000 | $7K | 9/28/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TNXP Secures Second Medicare Agreement for TONMYA
Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.
TNXP Secures Second Medicare Agreement for TONMYA. Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.